Lung Cancer

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).

Jessica Jiyeong Lin, MD, discusses rare oncogenic drivers and elaborates on the updated efficacy analyses that were presented at the 2019 ASCO Annual Meeting.

Alice T. Shaw, MD, PhD, provides an overlay of current treatment strategies in ALK-positive NSCLC and highlights research on the horizon.

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Inga T. Lennes, MD, MBA, MPH, discusses the recommended screening protocol for patients at risk for lung cancer, maintaining patients post-screening, and how physicians can best assist this patient population.

Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.

Heather Wakelee, MD, discusses the rationale and findings for two combination regimens in EGFR-mutant non-small cell lung cancer, as well as the implications for our understanding of mechanisms of resistance.

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).

Robert C. Doebele, MD, PhD, discusses a retrospective trial comparing the efficacy of entrectinib with crizotinib in the treatment of patients with ROS1-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Inga T. Lennes, MD, MBA, MPH, medical director, Ambulatory Services, director of clinical quality, Massachusetts General Hospital Cancer Center, discusses aspects of lung cancer screening.

Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses the numerous ALK inhibitors available in the treatment of ALK-positive non–small cell lung cancer, ongoing efforts to combat resistance, and sequencing challenges that have emerged.

Durvalumab combined with standard etoposide and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard chemotherapy alone as a first-line treatment in patients with extensive-stage small cell lung cancer, meeting the primary endpoint of the phase III CASPIAN trial (NCT03043872).

Paul K. Paik, MD, discussed using tepotinib—a highly selective, ATP-competitive, reversible, potent MET TKI—to treat patients with non–small cell lung cancer with MET exon 14 skipping mutations.

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses emerging treatment approaches in small cell lung cancer (SCLC).